Clinical Scorecard: The Role of Dysbiotic Microbiota in the Advancement of Chronic Kidney Disease: Findings from a Longitudinal Study on CKD and the Microbiome
At a Glance
Category
Detail
Condition
Chronic Kidney Disease (CKD)
Key Mechanisms
Dysbiosis leads to the production of uraemic toxins that exacerbate CKD progression.
Target Population
Patients with non-dialysis CKD
Care Setting
Nephrology clinics and research settings
Key Highlights
Dysbiosis in CKD is linked to increased levels of uraemic toxins.
Uraemic toxins contribute to inflammation and fibrosis in CKD.
Plant-based, low-protein diets may mitigate microbiome-related CKD progression.
Indoxyl sulfate and p-cresyl sulfate are significant candidates for CKD progression.
Gut microbiome alterations can accelerate kidney damage.
Guideline-Based Recommendations
Diagnosis
Assess gut microbiome composition in CKD patients.
Monitor plasma levels of uraemic toxins.
Management
Consider dietary interventions, such as plant-based, low-protein diets.
Monitoring & Follow-up
Track changes in estimated glomerular filtration rate (GFR) and microbiome composition.
Risks
Increased risk of CKD progression due to dysbiosis and uraemic toxins.
Patient & Prescribing Data
Patients with chronic kidney disease, particularly those with altered gut microbiota.
Dietary modifications may help in managing CKD progression.
Clinical Best Practices
Regularly evaluate gut health in CKD patients.
Implement dietary strategies to support gut microbiome balance.
